Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 9/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.50 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.50 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.50 |
| ▸ | RARB | P10826 | 1/20 | 0.50 |
| ▸ | RARG | P13631 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4915632 | 1.00 | PTGIR (0.58) | PTGIRTSHRPTGER4PTGER2HPGD | |
| SCHEMBL9943423 | 1.00 | PTGIR (0.58) | PTGIRTSHRPTGER4PTGER2HPGD | |
| SCHEMBL4915651 | 1.00 | PTGIR (0.58) | PTGIRTSHRPTGER4PTGER2HPGD | |
| SCHEMBL24244641 | 0.87 | PTGIR (0.65) | PTGIRTSHRPTGER4PTGER2HPGD | |
| SCHEMBL958202 | 0.83 | PTGIR (0.68) | PTGIRTSHRPTGER4PTGER2HPGD | |
| SCHEMBL958200 | 0.83 | PTGIR (0.68) | PTGIRTSHRPTGER4PTGER2HPGD | |
| SCHEMBL958197 | 0.83 | PTGIR (0.68) | PTGIRTSHRPTGER4PTGER2HPGD | |
| SCHEMBL10879707 | 0.82 | PTGIR (0.58) | PTGIRTSHRPTGER4PTGER2HPGD | |
| SCHEMBL22489095 | 0.81 | PTGIR (0.67) | PTGIRTSHRPTGER4PTGER2HPGD | |
| SCHEMBL960741 | 0.80 | PTGIR (0.78) | PTGIRTSHRPTGER4PTGER2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305304-A1 | IMMUNOPOTENTIATING AGENT COMPRISING EP1 AGONIST | National University Corporation Hamamatsu University School of Medicine (JP) | 2011-04-06 | — | — | EP | claimed |
| US-20110038884-A1 | IMMUNOPOTENTIATING AGENT COMPRISING EP1 AGONIST | NATIONAL UNIVERSITY CO., HAMAMATSU UNIVER. SCHOOL OF MEDICINE (JP) | 2011-02-17 | — | — | US | claimed |
| US-20260144801-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MUSCLE CONDITIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260022403-A1 | VCN ENHANCER COMPOSITIONS AND METHODS OF USING THE SAME | BLUEBIRD BIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250186415-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | disclosed |
| EP-4538365-A2 | COMPOSITIONS AND METHODS FOR MUSCLE REGENERATION USING PROSTAGLANDIN E2 | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20250090549-A1 | COMPOSITIONS AND METHODS FOR MUSCLE REGENERATION USING PROSTAGLANDIN E2 | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-03-20 | — | — | US | disclosed |
| US-12234476-B2 | VCN enhancer compositions and methods of using the same | BLUEBIRD BIO, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20250041211-A1 | OPHTHALMIC PREPARATION AND APPLICATION THEREOF IN TREATMENT OF PRESBYOPIA | Eye Hospital, Wenzhou Medical University (CN) | 2025-02-06 | — | — | US | disclosed |
| US-20240423970-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2024-12-26 | — | — | US | disclosed |
| US-20240415849-A1 | COMPOSITIONS AND METHODS FOR MUSCLE REGENERATION USING PROSTAGLANDIN E2 | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-12-19 | — | — | US | disclosed |
| US-8436026-B2 | Treating lung diseases selected from acute pneumonia, pulmonary fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), and asthma by administering (E)-[5-[2-[1-phenyl-1-(3-pyridyl)methylideneaminoxy]ethyl]-7,8-dihydronaphthalen-1-yloxy]acetic acid or a salt thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-07 | — | — | US | disclosed |
| EP-1563846-B1 | ENDOGENOUS REPAIR FACTOR PRODUCTION PROMOTERS | ONO PHARMACEUTICAL CO (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2305304-A1 | IMMUNOPOTENTIATING AGENT COMPRISING EP1 AGONIST | National University Corporation Hamamatsu University School of Medicine (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-20110038884-A1 | IMMUNOPOTENTIATING AGENT COMPRISING EP1 AGONIST | NATIONAL UNIVERSITY CO., HAMAMATSU UNIVER. SCHOOL OF MEDICINE (JP) | 2011-02-17 | — | — | US | disclosed |
| US-7547715-B2 | Endogenous repair factor production accelerator | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-06-16 | — | — | US | disclosed |
| US-20080312326-A1 | Method for the Prevention and/or Treatment of Neurodegenerative Diseases Characterized by Administering and Ep1 Receptor Antagonist | THE JOHN HOPKINS UNIVERSITY (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080299089-A1 | ENDOGENEOUS REPAIR FACTOR PRODUCTION PROMOTERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-04 | — | — | US | disclosed |
| US-20060069018-A1 | Endogenous repair factor production promoters | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-30 | — | — | US | disclosed |
| EP-1563846-A1 | ENDOGENOUS REPAIR FACTOR PRODUCTION PROMOTERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022403-A1 | VCN ENHANCER COMPOSITIONS AND METHODS OF USING THE SAME | PTGES2, POLN, HPGDS | PTGIR 39/4885TSHR 4552/4885PTGER4 18/4885 |
| US-20080312326-A1 | Method for the Prevention and/or Treatment of Neurodegenerative Diseases Characterized by Administering and Ep1 Receptor Antagonist | PTGER1, PSEN1, EPN1 | PTGIR 27/4885TSHR 784/4885PTGER4 41/4885 |
| US-20080299089-A1 | ENDOGENEOUS REPAIR FACTOR PRODUCTION PROMOTERS | PTGER4, PTGIR, PTGER1 | PTGIR 2/4885TSHR 2465/4885PTGER4 1/4885 |
| US-20110038884-A1 | IMMUNOPOTENTIATING AGENT COMPRISING EP1 AGONIST | PTGER1, CD69, CD4 | PTGIR 28/4885TSHR 1864/4885PTGER4 9/4885 |
| US-20060069018-A1 | Endogenous repair factor production promoters | PTGIR, PTGER4, PTGER1 | PTGIR 1/4885TSHR 1968/4885PTGER4 2/4885 |
| US-20260144801-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MUSCLE CONDITIONS | CPT1B, HPGD, PTGES | PTGIR 42/4885TSHR 2274/4885PTGER4 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.